Integrating pan-immune-inflammation value into personalized survival prediction of nasopharyngeal carcinoma: a large-scale long-term retrospective study

作者：Wenchao Li, Weiqiong Ni, Yuling Zhang, Yong-Miao Lin, Ao-Qiang Chen, Zhi‐Qing Long, Si‐Fen Wang, Fangfang Duan, Chao Zhang, Xin Huang, Dehuan Xie, Wen Xia, Shasha Du, Xin Hua · 发表于：BMC Cancer · 年份：2025 · DOI：10.1186/s12885-025-14413-4 · 被引用次数：6 · 研究领域：Cancer-related molecular mechanisms research、Inflammatory Biomarkers in Disease Prognosis、Cancer Immunotherapy and Biomarkers

BACKGROUND: Despite concurrent chemoradiotherapy (CCRT) being the standard treatment for locally advanced nasopharyngeal carcinoma (NPC), there remains considerable variability in survival outcomes among patients with the same tumor-node-metastasis (TNM) staging. This study aims to evaluate the prognostic significance of the pretreatment Pan-Immune-Inflammation Value (PIV), an integrative marker of immune-inflammatory status, in NPC patients undergoing CCRT. METHODS: A total of 860 NPC patients treated with platinum-based CCRT were included in this retrospective study. PIV was derived from pretreatment peripheral blood counts, categorizing patients into high-PIV (> 244.4) and low-PIV (≤ 244.4) cohorts. Overall survival (OS) rates were estimated using Kaplan-Meier methods and analyzed through Cox proportional hazards models. A PIV-based prognostic nomogram was developed and subsequently validated. RESULTS: Patients classified with low PIV exhibited markedly improved OS compared to those with high PIV (HR = 0.559, 95% CI: 0.415–0.753, P < 0.001). In the multivariate analysis, PIV emerged as an independent prognostic indicator, alongside age, T stage, N stage, and body mass index (BMI). Furthermore, the PIV-based nomogram demonstrated enhanced prognostic accuracy (C-index: 0.680, 95% CI: 0.641–0.719) when contrasted with the traditional TNM staging system (C-index: 0.638, 95% CI: 0.573–0.703). CONCLUSIONS: The pretreatment PIV serves as an independent prognostic factor in NPC pa...